secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024430
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics Q3 2022 net loss $16.2M; cash $98.7M; pipeline progress highlighted
--------------------------------------------------------------------------------

- Cash, cash equivalents, restricted cash equivalents and marketable securities totaled $98.7M at Sept 30, 2022, down from $117.5M at Dec 31, 2021.
- Net loss of $16.2M compared to $28.7M in Q3 2021; R&D expenses $9.1M, G&A expenses $7.2M.
- RT-102 Phase 1 Part 2 repeat-dose data expected in Q4 2022; positive Part 1 showed 300-400% greater bioavailability vs subcutaneous Forteo.
- RT-111 (ustekinumab biosimilar) preclinical development announced; Phase 1 planned in 2023.
- $30M committed loan from Avenue Venture Opportunities; up to $150M at-the-market equity offering program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017022024430/0000950170-22-024430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017022024430/rani-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer